Additive-induced metastable single crystal of mefenamic acid

Pharmaceutical Research

Volumn 23, Issue 10, 2006, Pages 2375-2380

  Lee, Eun Hee ^a   Byrn, Stephen R ^a   Carvajal, M Teresa ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Flufenamic acid; Mefenamic acid; Polymorph selection; Single crystal; XRPD

Indexed keywords

FLUFENAMIC ACID; MEFENAMIC ACID;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; HYDROGEN BOND; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SOLUBILITY; THEORETICAL STUDY; X RAY DIFFRACTION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; FLUFENAMIC ACID; MEFENAMIC ACID; MODELS, MOLECULAR; SOLUBILITY; X-RAY DIFFRACTION;

EID: 33749424960     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9045-y     Document Type: Article

References (26)

1. S. R. Byrn, R. R. Pfeiffer, and J. G. Stowell. Solid-State Chemistry of Drugs. Second Edition. SSCI Inc. (1999).
2. U.S. Food and Drug Administration. Meeting Scientific Considerations of Polymorphism in Pharmaceutical Solids: Abbreviated New Drug Applications. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3900B1_04_Polymorphism.htm (accessed 12/15/2005), part of U.S. Food and Drug Administration. http://www.fda.gov (accessed 12/15/2005).
3. S. R. Vippagunta, H. G. Brittain, and D. J. W. Grant. Crystalline solids. Adv. Drug Deliv. Rev. 48:3-26 (2001).
4. L. Addadi, Z. Berkovitch-Yellin, N. Domb, E. Gait, M. Lahav, and L. Leiserowitz. Resolution of conglomerates by stereo-selective habit modifications. Nature. 296:21-26 (1982).
5. Z. Berkovitch-Yellin, L. Addadi, M. Idelson, L. Leiserowitz, and M. Lahav. Absolute configuration of chiral polar crystals. Nature. 296:27-34 (1982).
6. L. Addadi, Z. Berkovitch-Yellin, I. Weissbuch, M. Lahav, and L. Leiserowitz. The use of "Enantiopolar directions in centrosymmetric crystals for direct assignment of absolute configuration of chiral molecules: Application to the system serine/threonine. J. Am. Chem. Soc. 104:2075-2077 (1982).
7. I. Weissbuch, L. Addadi, Z. Berkovitch-Yellin, E. Gati, S. Weinstein, M. Lahav, and L. Leiserowitz. Centrosymmetric crystals for the direct assignment of the absolute configuration of chiral molecules. Application to the α-amino acid by their effect on glycine crystals. J. Am. Chem. Soc. 105:6615-6621 (1983).
8. R. J. Flower. Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev. 26:33-67 (1974).
9. S. L. A. Munro and D. J. Craik. NMR conformational studies of fenamate non-steroidal anti-inflammatory drugs. Magn. Reson. Chem. 32:335-342 (1994).
10. J. J. Lozano, R. Pouplanar, M. Lopez, and J. Ruiz. Conformational analysis of the anti-inflammatory fenamates: a molecular mechanics and semiempirical molecular orbital study. J. Mol. Struct. (Theochem) 335:215-227 (1995).
11. V. Dhanaraj and M. Vijayan. Structural studies of analgesics and their interactions. XII. Structure and interactions of anti-inflammtory fenamtes. A concerted crystallographic and theoretical conformational study. Acta Crystallogr. B. 44:406-412 (1988).
12. A. J. Aguiar and J. E. Zelmer. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J. Pharm. Sci. 58:83-987 (1969).
13. S. Romero, B. Escalera, and P. Bustamante. Solubility behavior of polymorphs I and II of mefenamic acid in solvent mixtures. Int. J. Pharm. 178:193-202 (1999).
14. A. Adam, L. Schrimpl, and P. C. Schmidt. Some physicochemical properties of mefenamic acid. Drug Dev. Ind. Pharm. 26:477-487 (2000).
15. A. Adam, L. Schrimpl, and P. C. Schmidt. Factors influencing capping and cracking of mefenamic acid tablets. Drug Dev. Ind. Pharm. 26:489-497 (2000).
16. R. Panchagnula, P. Sundaramurthuy, O. Pillai, S. Agrawal, and Y. Ashok Raj. Solid-state characterization of mefenamic acid. J. Pharm. Sci. 93:1019-1029 (2004).
17. T. Umeda, N. Ohnishi, T. Yokohama, T. Kuroda, Y. Kita, K. Kuroda, E. Tatsumi, and Y. Matsuda. A kinetic study on the isothermal transition of polymorphic forms of tolbutamide and mefenamic acid in the solid state at high temperatures. Chem. Pharm. Bull. 33:2073-2078 (1985).
18. J. F. McConnell and F. Z. Company. N-(2,3-xylyl) anthranilic acid, C15H15NO2 mefenamic acid. Cryst. Struct. Commun. 5:861-864 (1976).
19. Z. Otwinowski and W. Minor. Methods Enzymol 276:307-326 (1997).
20. Bruker, XPREP in SHELXTL version 6.12, Bruker AXS Inc., Madison, Wisconsin, USA. (2002).
21. M. C. Burla, R. Caliandro, M. Camali, B. Carrozzini, G. L. Cascarano, L. De Caro, D. Giacovazzo, G. Polidori, and R. Spagna. J. Appl. Crystallogr. 38:381-388 (2005).
22. G. M. SheldrickSHELXL97 A Program for Crystal Structure Refinement, University of Gottingen, Germany, 1997.
23. Vishweshwar, P. McMahon, J. A. Oliveira, M. Peterson, M. L. Zaworotko, and J. Zaworotko. The predictably elusive form II of aspirin. J. Am. Chem. Soc. 127:16802-16803 (2005).
24. H. M. Krishna Murthy, T. N. Bhat, and M. Bijayan. Structure of a new crystal form of 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid (flufenamic acid). Acta Crystallogr., Sect.B:Struct. Crystallogr. Cryst. Chem. 38:315-317 (1982).
25. H. Xiarong, J. G. Stowell Xiaorong, K. R. Morris, R. R. Pfeiffer, G. Hui Li, P. Stahly, and S. R. Bryn. Stabilization of a metastable polymorph of 4-methyl-2-nitroacetanilide by isomorphic additives. Cryst. Growth Des. 1:305-312 (2001).
26. K. Y. Chow, J. Go, M. Mehdizadeh, and D. J. W. Grant. Modification of adipic acid crystals: influence of growth in the presence of fatty acid additives on crystal properties. Int. J. Pharm. 20:3-34 (1984).